Skip to content
Open access

Integrative genomic profiling identifies MLPH as a candidate gene in prostate cancer

Jul 2026 · Frontiers in Medicine · Vol 13 · 0 citations · 85 references
Medicine

TL;DR

Findings support a potential role for MLPH in PCa biology, particularly in relation to vesicle trafficking and tumor differentiation, and links its regulatory signal to tumor-context expression, protein-level evidence, cellular localization, and clinically relevant molecular features.

Abstract

Background Prostate cancer (PCa) is a highly heterogeneous malignancy with complex genetic underpinnings. This study integrates multi-omics data to prioritize candidate susceptibility genes and evaluate their functional and clinical significance in PCa pathogenesis. Materials and methods We integrated PCa GWAS summary statistics with GTEx v8 expression quantitative trait locus reference panels to perform cross-tissue and single-tissue transcriptome-wide association studies. Candidate signals were refined using conditional analysis, MAGMA and fastBAT gene-level tests, Summary data-based Mendelian randomization, and Bayesian colocalization. Tumor-context cis-eQTL evidence from TCGA-PRAD was incorporated to prioritize regulatory signals retained in prostate cancer tissues. Prioritized candidates were further assessed using transcriptomic datasets, Human Protein Atlas immunohistochemistry, single-cell RNA-seq analysis, histological grading, preoperative PSA, and established genomic risk signatures. Gene network and pathway enrichment analyses were performed to explore potential biological context. Results The integrative genetic analyses identified 23 consensus candidate genes supported by multiple association frameworks. SMR and Bayesian colocalization further narrowed the candidate list, and tumor-context cis-eQTL analysis in TCGA-PRAD retained MLPH as the final prioritized candidate. The lead variant rs7582964 was significantly associated with MLPH expression in PRAD tumor tissues. MLPH was upregulated in PCa tissues compared with normal prostate tissues in TCGA-PRAD and showed concordant expression patterns in an independent GEO cohort and Human Protein Atlas immunohistochemistry data. Single-cell transcriptomic analysis localized MLPH expression mainly to epithelial cells, with the strongest signal observed in tumor epithelial cells. Clinically, MLPH expression was associated with histological differentiation, with reduced expression in the most poorly differentiated tumors. Lower MLPH expression also correlated with higher preoperative PSA and higher Decipher-like genomic risk scores. Functional analyses linked MLPH to vesicle-mediated transport, exocytosis, and hormone-related signaling pathways. Discussion and conclusion This integrative genomic analysis prioritizes MLPH as a candidate susceptibility gene for PCa and links its regulatory signal to tumor-context expression, protein-level evidence, cellular localization, and clinically relevant molecular features. These findings support a potential role for MLPH in PCa biology, particularly in relation to vesicle trafficking and tumor differentiation.

Read PDF

Similar papers

Open access Sep 2026

Integrative genetic and transcriptomic analyses prioritize CDC16 as a candidate marker for gastric cancer.

BackgroundGastric cancer (GC) remains a major cause of cancer-related mortality, and biomarkers for early detection are needed.MethodsStomach and blood expression quantitative trait loci were integrated with two GC genome-wide association studies using Mendelian randomization (MR), Bayesian colocalization, and summary-...

Fan Xue, Dao-Cheng Wu, Xu Zhang · 0 citations
Open access Aug 2026

Multi-omics identification and functional validation of signal regulatory protein gamma as a prognostic biomarker and immune regulator in head and neck squamous cell carcinoma

SIRPG is identified as an immune-related prognostic hub and context-dependent tumor-cell regulator associated with apoptosis, immune communication and spatial microenvironmental organization in HNSCC.

Jiaqi Tang, Yu-Lun He, Yu-Qi Wang et al. · 0 citations
Open access Aug 2026

Multi-level Transcriptomic and Machine-learning Analyses Identify MZT1 as a Proliferation-associated Prognostic Marker in Lung Adenocarcinoma

MZT1 is a proliferation-associated marker that integrates clinical risk, transcriptional programs, cellular heterogeneity, and predictive modeling in LUAD, providing a potential framework for biomarker development and risk stratification.

Dahlak Daniel Solomon, Hui-Ru Lin, Yung-Kuo Lee et al. · 0 citations
Open access Aug 2026

Integrated transcriptomic and immune-associated network analysis of breast cancer patient-derived organoids reveals candidate inflammatory biomarkers

It is suggested that IL1RAP and IRF2BP2 may be important in immune-related and candidated biomarker identification in breast cancer PDOs, and an integrated transcriptomic, enrichment and network-based analyses for a robust strategy for biomarker discovery are integrated.

S. Scippa, A. Balestrieri, M. Zanfardino et al. · 0 citations
Aug 2026

ATP13A2 Promotes Endothelial Angiogenic Phenotypes and Is Associated With Poor Prognosis in Liver Hepatocellular Carcinoma.

Liver hepatocellular carcinoma (LIHC) is a molecularly heterogeneous malignancy for which additional genetically supported biomarkers and functional regulators remain to be identified. We aimed to identify candidate genes through integrative genetic and transcriptomic screening, then determine the cellular context and...

Qi Liu, Yuyang Liu, Jun-Yi Chen et al. · 0 citations
Open access Jan 2026

From Germline Variants to Tumor Outcome: GWAS‐Based Functional Genomics Prioritizes Colorectal Cancer Susceptibility Genes and Links SMAD9 to Prognosis

Integrating statistical genetics, regulatory prediction, and locus‐directed experiments prioritized SMAD9, MAP3K2, FADS1, and ACTR1B as CRC susceptibility genes, and placed experimental bounds on the proposed MAP3K2 and ACTR1B mechanisms.

Chengguang Hu, Guang Yang, Han Xiong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.